Show simple item record

dc.contributor.authorDowsett, M
dc.contributor.authorSestak, I
dc.contributor.authorBuus, R
dc.contributor.authorLopez-Knowles, E
dc.contributor.authorMallon, E
dc.contributor.authorHowell, Anthony
dc.contributor.authorForbes, J
dc.contributor.authorBuzdar, A
dc.contributor.authorCuzick, J
dc.date.accessioned2015-07-21T10:31:18Zen
dc.date.available2015-07-21T10:31:18Zen
dc.date.issued2015-06-15en
dc.identifier.citationEstrogen Receptor Expression in 21-Gene Recurrence Score Predicts Increased Late Recurrence for Estrogen-Positive/HER2-Negative Breast Cancer. 2015, 21 (12):2763-70 Clin Cancer Resen
dc.identifier.issn1078-0432en
dc.identifier.pmid26078431en
dc.identifier.doi10.1158/1078-0432.CCR-14-2842en
dc.identifier.urihttp://hdl.handle.net/10541/560787en
dc.description.abstractTo identify the individual genes or gene modules that lead to the OncoptypeDx 21-gene recurrence score's reduced performance after 5 years and thereby identify indices of residual risk that may guide selection of patients for extended adjuvant therapy.
dc.language.isoenen
dc.rightsArchived with thanks to Clinical cancer research : an official journal of the American Association for Cancer Researchen
dc.titleEstrogen Receptor Expression in 21-Gene Recurrence Score Predicts Increased Late Recurrence for Estrogen-Positive/HER2-Negative Breast Canceren
dc.typeArticleen
dc.contributor.departmentRoyal Marsden Hospital and Breakthrough Breast Cancer Centre, Institute of Cancer Research, London, United Kingdomen
dc.identifier.journalClinical Cancer Researchen
html.description.abstractTo identify the individual genes or gene modules that lead to the OncoptypeDx 21-gene recurrence score's reduced performance after 5 years and thereby identify indices of residual risk that may guide selection of patients for extended adjuvant therapy.


This item appears in the following Collection(s)

Show simple item record